Results 301 to 310 of about 5,067,781 (348)
Some of the next articles are maybe not open access.
Tranexamic Acid in Pediatric Scoliosis Surgery
Spine, 2021In this randomized trial that included 166 adolescent idiopathic scoliosis patients aged between 10 to 21 years old who underwent posterior spinal fusion surgery with a mean duration of 120 minutes by two attending surgeons in a single academic ...
M. Hasan +5 more
semanticscholar +1 more source
Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial.
Journal of the American Medical Association (JAMA)Importance Tranexamic acid reduces bleeding and blood transfusion in many types of surgery, but its effect in patients undergoing liver resection for a cancer-related indication remains unclear.
Paul J. Karanicolas +44 more
semanticscholar +1 more source
TRANEXAMIC ACID AND CORNEAL DETURGESCENCE
Acta Ophthalmologica, 1979Recent work has demonstrated decreased corneal thickness in patients with Fuch's dystrophy and in patients following cataract extraction who were given systemic tranexamic acid. Although tranexamic acid is a known antifibrinolytic drug its mechanism in reducing corneal thickness is not known.
James G. Buyer +2 more
openaire +3 more sources
Journal of Cosmetic Dermatology, 2021
Tranexamic acid (TA) can prevent melanocyte activation by various stimuli. Combining TA with either hydroquinone 4% or Q‐switched Nd:YAG laser may be associated with greater improvement of melasma.
Abdelaal M. Elkamshoushi +2 more
semanticscholar +1 more source
Tranexamic acid (TA) can prevent melanocyte activation by various stimuli. Combining TA with either hydroquinone 4% or Q‐switched Nd:YAG laser may be associated with greater improvement of melasma.
Abdelaal M. Elkamshoushi +2 more
semanticscholar +1 more source
Journal of Cosmetic Dermatology, 2021
Treatment options for erythematotelangiectatic rosacea (ETR) are still scarce. Tranexamic acid (TXA) is an antifibrinolytic drug that was recently used for the treatment of ETR.
Najla Daadaa +7 more
semanticscholar +1 more source
Treatment options for erythematotelangiectatic rosacea (ETR) are still scarce. Tranexamic acid (TXA) is an antifibrinolytic drug that was recently used for the treatment of ETR.
Najla Daadaa +7 more
semanticscholar +1 more source
BJU International, 2021
To assess the efficacy and safety of single‐dose tranexamic acid on the blood transfusion rate and outcomes of patients with complex kidney stones undergoing percutaneous nephrolithotomy (PCNL).
C. Batagello +10 more
semanticscholar +1 more source
To assess the efficacy and safety of single‐dose tranexamic acid on the blood transfusion rate and outcomes of patients with complex kidney stones undergoing percutaneous nephrolithotomy (PCNL).
C. Batagello +10 more
semanticscholar +1 more source
A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss
Annals of Surgery, 2020Supplemental Digital Content is available in the text Objective: To review the efficacy and safety of a single dose of intravenous tranexamic acid (TXA) given preoperatively. Summary Background Data: TXA is a synthetic antifibrinolytic that has been used
M. Heyns +3 more
semanticscholar +1 more source
Tranexamic Acid in Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-analysis
American Journal of Sports Medicine, 2021Background: Hemarthrosis after anterior cruciate ligament (ACL) reconstruction procedures can delay rehabilitation and have toxic effects on the cartilage and synovium.
William L. Johns +5 more
semanticscholar +1 more source
Diffusion of Tranexamic Acid to the Joint
Acta Orthopaedica Scandinavica, 1976Tranexamic acid (Cyklokapron, Kabi, Stockholm) in a dose of 10 mg per kg body weight was given i.v. to 17 patients at various intervals before operation on the knee joint, in order to elucidate the diffusion of the drug to the joint fluid and the synovial membrane.
Olle Eriksson +2 more
openaire +3 more sources
Hospital Pharmacy, 2010
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
Dennis J. Cada +2 more
openaire +2 more sources
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
Dennis J. Cada +2 more
openaire +2 more sources